BlackRock’s Kezar Life Sciences KZR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-100,064
| Closed | -$742K | – | 5815 |
|
|
2026
Q1 | $742K | Buy |
100,064
+1,380
| +1% | +$8.98K | ﹤0.01% | 4423 |
|
|
2025
Q4 | $621K | Buy |
98,684
+581
| +0.6% | +$3.39K | ﹤0.01% | 4432 |
|
|
2025
Q3 | $383K | Buy |
98,103
+432
| +0.4% | +$1.77K | ﹤0.01% | 4526 |
|
|
2025
Q2 | $447K | Buy |
97,671
+15,057
| +18% | +$64.5K | ﹤0.01% | 4473 |
|
|
2025
Q1 | $403K | Sell |
82,614
-241
| -0.3% | -$1.46K | ﹤0.01% | 4452 |
|
|
2024
Q4 | $557K | Sell |
82,855
-3
| -0% | -$22 | ﹤0.01% | 4385 |
|
|
2024
Q3 | $641K | Sell |
82,858
-179
| -0.2% | -$1.08K | ﹤0.01% | 4273 |
|
|
2024
Q2 | $498K | Sell |
83,037
-378,662
| -82% | -$2.88M | ﹤0.01% | 4343 |
|
|
2024
Q1 | $4.16M | Sell |
461,699
-20,028
| -4% | -$182K | ﹤0.01% | 3747 |
|
|
2023
Q4 | $4.56M | Sell |
481,727
-13,502
| -3% | -$119K | ﹤0.01% | 3727 |
|
|
2023
Q3 | $5.89M | Sell |
495,229
-13,686
| -3% | -$243K | ﹤0.01% | 3598 |
|
|
2023
Q2 | $12.5M | Buy |
508,915
+63,116
| +14% | +$1.64M | ﹤0.01% | 3306 |
|
|
2023
Q1 | $14M | Buy |
445,799
+22,708
| +5% | +$1.31M | ﹤0.01% | 3148 |
|
|
2022
Q4 | $29.8M | Buy |
423,091
+12,598
| +3% | +$934K | ﹤0.01% | 2808 |
|
|
2022
Q3 | $35.3M | Buy |
410,493
+52,514
| +15% | +$5.1M | ﹤0.01% | 2702 |
|
|
2022
Q2 | $29.6M | Buy |
357,979
+68,272
| +24% | +$6.02M | ﹤0.01% | 2864 |
|
|
2022
Q1 | $48.1M | Buy |
289,707
+21,005
| +8% | +$3.01M | ﹤0.01% | 2617 |
|
|
2021
Q4 | $44.9M | Buy |
268,702
+5,520
| +2% | +$623K | ﹤0.01% | 2724 |
|
|
2021
Q3 | $22.7M | Buy |
263,182
+3,202
| +1% | +$212K | ﹤0.01% | 3195 |
|
|
2021
Q2 | $14.1M | Sell |
259,980
-981
| -0.4% | -$55.7K | ﹤0.01% | 3501 |
|
|
2021
Q1 | $15.6M | Buy |
260,961
+9,052
| +4% | +$529K | ﹤0.01% | 3321 |
|
|
2020
Q4 | $13.2M | Buy |
251,909
+52,479
| +26% | +$2.92M | ﹤0.01% | 3230 |
|
|
2020
Q3 | $9.65M | Sell |
199,430
-6,660
| -3% | -$319K | ﹤0.01% | 3239 |
|
|
2020
Q2 | $10.7M | Buy |
206,090
+26,301
| +15% | +$1.33M | ﹤0.01% | 3146 |
|
|
2020
Q1 | $7.84M | Buy |
179,789
+88,909
| +98% | +$3.62M | ﹤0.01% | 3120 |
|
|
2019
Q4 | $3.64M | Buy |
90,880
+989
| +1% | +$30.4K | ﹤0.01% | 3589 |
|
|
2019
Q3 | $2.95M | Buy |
89,891
+5,452
| +6% | +$263K | ﹤0.01% | 3634 |
|
|
2019
Q2 | $6.51M | Buy |
84,439
+20,881
| +33% | +$3.25M | ﹤0.01% | 3442 |
|
|
2019
Q1 | $11.3M | Buy |
63,558
+38,965
| +158% | +$7.68M | ﹤0.01% | 3056 |
|
|
2018
Q4 | $5.8M | Buy |
24,593
+448
| +2% | +$109K | ﹤0.01% | 3348 |
|
|
2018
Q3 | $5.17M | Buy |
24,145
+23,145
| +2,315% | +$4.04M | ﹤0.01% | 3499 |
|
|
2018
Q2 | $173K | Buy |
+1,000
| New | +$174K | ﹤0.01% | 4338 |
|
BlackRock's KZR Position: Q2 2026 in Review
BlackRock sold out of Kezar Life Sciences (KZR) in Q2 2026, closing a stake of 100,064 shares — an estimated $742K sold.
BlackRock first reported a position in KZR in Q2 2018 and held it in 32 quarters. The position peaked at $48.1M in Q1 2022. 0 funds tracked by Wall St. Rank hold KZR as of Q2 2026.
- BlackRock reported no remaining Kezar Life Sciences position as of Q2 2026 after selling out during the quarter.
- BlackRock sold 100,064 Kezar Life Sciences shares in Q2 2026, an estimated $742K.
- BlackRock first reported a position in Kezar Life Sciences in Q2 2018 and held it in 32 quarters.
- BlackRock's Kezar Life Sciences position peaked at $48.1M in Q1 2022.
- 0 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.